Melanoma: Keeping up with increasing incidence
The incidence of melanoma is increasing faster than any other cancer.1 Although most cases are treated early, 5-year survival rates for patients with metastatic disease remain low.2
Indoximod research targets advanced melanoma3
NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.4,5
1. Medscape. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. www.medscape.com/viewarticle/470300. Accessed October 3, 2015. 2. American Cancer Society. Melanoma skin cancer. http://www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf. Revised March 20, 2015. Accessed October 4, 2015. 3. National Institutes of Health. Study of IDO inhibitor in combination with ipilimumab for adult patients with metastatic melanoma. http://clinicaltrials.gov/ct2/show/record/NCT02073123. Accessed October 4, 2015. 4. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 5. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.